Lv61
2410 积分 2023-09-16 加入
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer
16天前
已完结
Clinical management of metastatic colorectal cancer in the era of precision medicine
16天前
已完结
How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation
16天前
已完结
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
16天前
已完结
Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer
3个月前
已完结
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
3个月前
已完结
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
3个月前
已完结
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
3个月前
已完结
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
3个月前
已完结
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
4个月前
已完结
皖公网安备34019202002308
